Skip to main content

Table 1 Baseline characteristics of participants in each study group

From: Impact of removing prescription co-payments on the use of costly health services: a pragmatic randomised controlled trial

 

Intervention n (%)

Control n (%)

Total n (%)

P value (chi-square or Fisher’s exact)

Age, Mean (SD)

60.3 (14.0)

61.5 (13.8)

60.8 (13.9)

0.10

Males N (%)

262 (44.7)

194 (41.5)

456 (43.3)

0.30

Ethnicitya

 European

288 (49.1)

247 (52.9)

535 (50.8)

 

 Māori

302 (51.5)

211 (45.2)

513 (48.7)

 

 Pacific Peoples

14 (2.4)

10 (2.1)

24 (2.3)

 

 Asian

6 (1.0)

5 (1.1)

11 (1.0)

 

 Other

44 (7.5)

50 (10.7)

94 (8.9)

 

 Missing

0 (0)

3 (0.6)

3 (0.3)

 

NZDep

0.49

 1–6

16 (2.7)

18 (3.9)

34 (3.2)

 

 7–8

134 (22.9)

113 (24.2)

247 (23.5)

 

 9–10

436 (74.4)

336 (71.9)

772 (73.3)

 

Ruralityb:

0.07

 Urban 1 (most urban)

0

0

0

 

 Urban 2

280 (47.8)

216 (46.3)

496 (47.1)

 

 Rural 1

227 (38.7)

170 (36.4)

397 (37.7)

 

 Rural 2

61 (10.4)

51 (10.9)

112 (10.6)

 

 Rural 3 (most rural)b

18 (3.1)

30 (6.4)

48 (4.6)

 

Medicines used 1 Feb 2019 – 31 Oct 2019c

 Number of new dispensings per person

29.83

29.82

  

 Number of different medicines per person

12

12

  
  1. aMultiple ethnicities could be given so numbers do not add up to 100%. Therefore, a P value is not presented. We used prioritized ethnicity to examine the difference between groups, and p = 0.18
  2. bGeographic classification for health (GCH) [40] 19% of the New Zealand population live in rural areas (1, 2 and 3)
  3. c “Before the study” is defined as 1 Feb 2019 to 31 October 2019. People start paying for 20 items at 1 Feb each year so this is an appropriate start date. After enrolling in the study the control group had an incentive to get as many medicines as possible before copayments started on 1 Feb 2020. Those in the intervention group had no such incentive, so to avoid any effect of the study on behaviour, we looked at the period before recruitment started